Equillium, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 24, 2021. The filing also reports unaudited fourth-quarter results. Equillium is a clinical-stage biotechnology company developing itolizumab (EQ001), an antibody targeting CD6. It had no product revenue and no approved products in its licensed territories.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $19.4 million | $17.6 million |
| General and administrative expense | $10.2 million | $9.1 million |
| Net loss | $29.8 million | $25.6 million |
| Net loss per share, basic and diluted | $1.46 | $1.47 |
| Cash used in operating activities | $24.6 million | $22.9 million |
| Cash, cash equivalents and short-term investments at year-end | $82.2 million | $53.1 million |
| Notes payable, carrying amount | $9.9 million | $9.7 million |
Fourth quarter 2020: Operating expenses were $9.0 million and net loss was $8.9 million, or $0.36 per share. Fourth-quarter 2019 operating expenses were $7.6 million and net loss was $7.6 million, or $0.44 per share.
Operating margins are not meaningful because the company had no revenue. At December 31, 2020, current assets were $85.2 million and current liabilities were $7.2 million. The company reported a $70.9 million accumulated deficit and $69.9 million in stockholders’ equity.
Changes versus 2019
- Net loss increased by $4.2 million. R&D expense rose $1.7 million, mainly from higher personnel costs and clinical development activity, partly offset by a $1.0 million Australian R&D tax incentive benefit.
- G&A expense increased $1.1 million, including higher compensation and consulting costs; 2020 also included $0.4 million of immediately vested retention-option expense.
- Interest expense increased to $1.1 million from $0.3 million, while interest income fell to $0.5 million from $1.4 million, reflecting lower investment yields.
- Operating cash use increased $1.7 million. Investing cash use increased to $18.6 million, largely reflecting purchases of short-term investments exceeding maturities.
- Financing provided $53.9 million, primarily from a $35.7 million net follow-on offering and $18.1 million net ATM proceeds. Shares outstanding rose to 24.8 million from 17.4 million at year-end 2019.
Pipeline, outlook and key risks
- aGVHD: November 2020 interim Phase 1b results reported an 80% overall response rate across the first three dose cohorts; seven of eight responding patients achieved complete response and one achieved very good partial response by Day 29. These are interim, small-cohort results, not confirmatory efficacy evidence. Management planned to report Phase 1b topline data in the first half of 2021. The independent monitoring committee recommended expansion of the 0.8 and 1.6 mg/kg cohorts.
- Lupus/lupus nephritis: Enrollment in the EQUALISE study resumed in July 2020 after a COVID-related pause. Management expected SLE cohort topline data in Q1 2021 and lupus nephritis interim data in the second half of 2021. The study was amended to allow higher doses, longer treatment and an open-label design.
- Uncontrolled asthma: Enrollment also resumed in July 2020, but remained challenging amid the pandemic and fewer asthma exacerbations. The protocol was amended to focus primarily on safety; topline data were expected in the second half of 2021.
- The company elected not to initiate its planned Phase 3 COVID-19 trial in November 2020 as the treatment landscape evolved.
- Management said year-end liquidity was expected to fund planned operations for at least 12 months from the filing date, but additional capital would be required to complete development and potential commercialization. In February 2021, Equillium raised approximately $30 million gross through a share-and-warrant offering.
- Key risks include clinical failure or delay, uncertain interpretation of interim data, COVID-related enrollment disruption, dependence on Biocon for manufacturing and licensed rights, financing needs and potential dilution, debt covenants and secured-lender remedies, regulatory approval uncertainty, and exposure to U.S. sanctions rules because the antibody is considered Cuban-origin. The company reported no litigation as of year-end.
- Debt: The company had borrowed $10 million under a secured loan facility, with interest at the greater of 8.25% or prime plus 3%; it did not meet the milestones required to access up to $10 million of additional borrowing by December 31, 2020. The loan matures June 1, 2024 and includes a 4.5% final payment fee.
Most important facts for investors to verify
- Updated clinical-trial results, patient counts, durability, safety findings and regulatory feedback for EQUATE, EQUALISE and EQUIP; compare final data with the cited interim results and timelines.
- Cash burn and financing runway after the February 2021 $30 million offering, including warrant terms, subsequent share issuance and remaining ATM capacity.
- Biocon license diligence milestones, territory and field limitations, manufacturing continuity, and potential milestone and royalty obligations.
- Loan repayment schedule, interest and covenant compliance, and the effect of the secured lender’s rights on liquidity.
- Whether the stated 12-month funding outlook remains valid as trial costs, enrollment and development plans evolve.